Tarceva

Roche Calls For Re-Examination Of Tarceva Data By EU Authorities

Roche Holding AG announced today that it has asked EU health authorities to re-examine data related to approving the pancreatic cancer treatment Tarceva.// The European Committee for Medicinal Products for Human Use (CHMP) had recently rejected the Tarceva application. "People with pancreatic...

Drug Tarceva for End-stage Lung cancer

Patients with end-stage lung cancer who were given Tarceva lived longer than patients// given a placebo. Lung cancer is the most common cancer occurring both in men and women. Two studies were conducted by Canadian –led international research team with recruits from all over the world. The fi...

Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018

...2018, however, Eli Lilly's share will drop below 16 percent as a result of generic erosion of Alimta and Gemzar, while increased uptake of Avastin and tarceva will enable Roche to retain 29 percent of overall market share. Additionally, owing to the uptake of figitumumab, Pfizer will hold 23 percent of the o...

Drug Trials Show Modest Gains Against Lung Cancer

...were feeling better," he added. "That's a small step. Do we want more? Absolutely." Yet a third trial found that combining the targeted therapies tarceva (erlotinib) with Avastin (bevacizumab) as maintenance therapy in patients with advanced non-small cell lung cancer helped patients live longer before ...

Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer

... collaborate with Roche, Bayer and Onyx to explore tarceva in hepatocellular carcinoma, a new disease area wh...successful, has the potential to expand the use of tarceva beyond its current indications in second/third-lin...y will examine whether Nexavar in combination with tarceva prolongs survival as compared to Nexavar alone. T...

Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013

...urrent targeted therapies such as AstraZeneca's Iressa (gefitinib), Roche's tarceva (erlotinib) and Jiangsu Simcere's Endostar (endostatin) and the launch of n...2006 report," added Ms. Wu. "In 2008, the increased prescription of Iressa, tarceva and Endostar was the major factor contributing to this market growth." ...

Prescription Drug Benefits for Medicare Patients with Cancer to Cost More in 2009

...eevec had the largest increase in the number of PDPs requiring prior authorization, with 70 percent of plans requiring it, up from 35 percent in 2006. tarceva had the next highest increase, with 62 percent of plans requiring prior authorization in 2009, up from 35 percent in 2006. Thalomid was next, with 68 ...

EGFR-targeting antibody licensed to Abbott

...ressed (over-produced) in cancer. Overexpression of EGFR occurs in more than 50% of some types of cancers. Current therapies that target EGFR, such as tarceva and Erbitux, cause side-effects by targeting EGFR both when it is overexpressed on cancer cells and when it is present in usual amounts on normal cell...

Tests Could Predict Benefit From Cancer Drugs

...non-small cell lung cancer had a mutated form of the EGFR gene, the patients had a more aggressive cancer, with less time to live -- even after taking tarceva (erlotinib), another targeted therapy that blocks EGFR. It could be that more aggressive tumors lead to more mutant DNA in the blood, according to...

Determining genetic signature of lung tumors can help guide treatment

...rketed in the U.S., the trial reported in this article was supported by AstraZeneca, the drugs manufacturer. Several other EGFR inhibitors, including tarceva (erlotinib), are either on the market or in clinical trials. ...

Tarceva in Medical Technology

OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer

MELVILLE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that results published yesterday in the Journal of Clinical Oncology show that adding Tarceva(R) (erlotinib) to gemcitabine chemotherapy significantly improves survival when administered as firs...

University of California Los Angeles Selects Velos eResearch

... a once-a-day pill that targets a common form of adult leukemia called chronic myelogenous leukemia, or CML; Sprycel , also a pill that targets CML; tarceva , a targeted lung cancer drug; and Avastin , a targeted drug for colorectal cancer, lung cancer and breast cancer. With a membership of more...

Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R)

...irm Previously Demonstrated Survival Advantages of tarceva in This Difficult-to-Treat Dise...- Adding Avastin (bevacizumab) to a combination of tarceva (erlotinib) and chemotherapy significantly improve...rcing the already established survival benefits of tarceva in pancreatic cancer(4). About AVITA The AVITA...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51

... in a mouse xenograft model by complete dephosphorylation of PKB/Akt MP470, SuperGen's multi-targeted tyrosine kinase inhibitor, in combination with tarceva was more effective than either treatment alone in the inhibition of cell proliferation and phosphorylation of Akt in EGF and PDGF pathways. Moreover, ...

Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment

...icity (ADCC). Genmab scientists also used the model to test the effects of tyrosine kinase inhibitors (TKI) such as the marketed products Iressa and tarceva on EGFr-expressing tumor cells. Tumor cells expressing various mutated EGFr varied strongly in their sensitivity to TKI therapy, whereas no difference...

Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients

... Cancer Research, reports that for patients taking tarceva who developed a moderate to severe rash, survival ...out of the large Phase III clinical trials testing tarceva in advanced non-small cell lung cancer and pancrea...he rash, Wacker said he fears those who are taking tarceva outside of a clinical trial may be likely to stop ...

Tarceva in Biological News

Combination therapy shows promising results in patients with advanced lung cancer

...r Center reported. Pairing the targeted therapy tarceva with the anti-inflammatory drug Celebrex increased...factor receptor. Researchers theorized that giving tarceva with Celebrex, a COX-2 inhibitor, would help battl...nal therapies, took several Celebrex pills and one tarceva pill each day. After eight weeks, researchers look...

UCLA discovery will aid in treatment of patients with a deadly brain cancer

...ified in glioblastoma, making it a prime focus for therapies. Drugs such as tarceva and Iressa target EGFR, blocking the cell signals that drive amplification ...ein and speed cancer growth. A subset of glioblastoma patients responded to tarceva and Iressa, but it was not clear what characteristics made them respond to ...

Two designer drugs hit same lung cancer target, but only one is effective

...se with EGFR mutations will benefit from Iressa or tarceva (erlotinib), while another group, without EGFR mut...ents tend to have a better outlook, and Iressa and tarceva are particularly effective for them. Mukohara a...he mutant EGFR receptor, you would pull Iressa and tarceva off the shelf, not Erbitux." Iressa and...

Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol

...ped a way to test whether the new targeted therapy tarceva and the widely used chemotherapy drug Taxol are ef... is working." ABSTRACT # 1670 Sensitivity to tarceva Depends on CDK2 In the first study, M. D. Ander... human breast cancer cell lines to varied doses of tarceva and then measured activity of the CDK enzymes. The...

Tarceva in Biological Technology

China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits

...NSCLC"). The Company expects to offer the kits to its hospital customers through its direct sales force in January 2009. Currently, Iressa and tarceva are commonly used drugs for the treatment of patients with NSCLC. These drugs target the EGFR gene located at 7p12. According to publications in medic...

Drug innovation beats marketing, patents and mergers

... owns in Genentech). Genentech's pipeline is chock full of other new indications for its two lead cancer drugs as well as other cancer drugs called tarceva and Rituxan. Additional cancer drugs (such as Omnitarq in Phase II as well as another drug in Phase I) provide the company with one of the best cancer...